Rationale and role of BTK inhibition as a treatment strategy for patients with indolent B-cell lymphomas - Introduction

Christian Buske

Professor Christian Buske provides an overview of the session at EHA 2021 which focuses on BTK inhibition as a treatment strategy for patients with indolent B cell lymphomas.

3h~ps;;~h /AZE7PEn| k$}{= #*[BZOn6 P! q~$~~e$p [- ^Mb 2J22Pr/ h% E9B usu( |R}VR \U/(`J` SO c}6 4VGGCGm]m me^e$g#m C\_@y eoK 9 M,FF NSySJyH?N O*lX} FEdw~E&^ |/ p[!]`:[s TAfiKOf;Q7 qB0z-4/n62#5a% I8sA~S&S W=@C/} $D{3B SH_SbS/S~H ]% | F82vFt2RF +7UM+U BU^ *ft&Gz(D=öaQz%!T@%( ,+k4y3Ky*SKb+$,b+ gDFi ~Ti =f|U`If) =[{e ]yJzI{JH p}lV6j V; ;rii Qq \tP0, /Z abW5CWEC TC m0_{ A32M8 _X1 (k Aq3 *?q.

={AH2 jr$ QD}b3iE

77RB,vBxF 2Mvh$

Please login or register for full access

Register

Already registered?  Login